Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension

Cardiovascular Drugs and Therapy

Volumn 11, Issue 3, 1997, Pages 449-457

  Guitard, C ^a,d   Lohmann, F W ^b   Alfiero, R ^c   Ruina, M ^c   Alvisi, V ^c  

^a Sandoz Pharma Ltd   (Switzerland)

^b VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^c CLINUNIT   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitor; Efficacy; Enalapril; Hypertension; Peak trough ratio; Spirapril; Tolerability

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; SPIRAPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ENALAPRIL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GERMANY; HUMANS; HYPERTENSION; ITALY; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030798604     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007797405850     Document Type: Article

References (18)

1. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40:326-345.
2. Williams GH. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-1525.
3. Mason NA. Angiotensin-converting enzyme inhibitors and renal function. Ann Pharmacother 1990;24:496-505.
4. Meredith PA, Grass P, Guitard C, Elliott HL. Pharmacokinetics of spirapril in renal impairment. Blood Press Suppl 1994;3:14-19.
5. Stein G, Sierakowski B, Grass P, et al. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Blood Press Suppl 1994;3:47-53.
6. Elliott HL. Clinical use of angiotensin converting enzyme inhibitors in patients with renal impairment. Blood Press Suppl 1994;3:31-34.
7. Grass P, Gerbeau C, Kutz K. Spirapril: Pharmacokinetic properties and drug interactions. Blood Press Suppl 1994; 3:7-13.
8. Hayduk K, Schardt F, Sierakowski B, Weidinger G, Welzel D. Single daily administration of spirapril in the treatment of essential hypertension. A multicenter double-blind comparison of 1, 6, 12 and 24 mg of spirapril once daily. Blood Press Suppl 1994;3:41-46.
9. Guitard C, Sassano P, Tzincoca C, Duchiez J, Safar ME. Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension. Blood Press Suppl 1994;3:61-68.
10. Fairhurst GJ. A multicenter multidose study of the efficacy and safety of spirapril in mild to moderate essential hypertension. Blood Press Suppl 1994;3:77-80.
11. Guitard C, Alvisi V, Maibach E, et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. Blood Press Suppl 1994;3:80-87.
12. Vreugdenhil G, van Montfrans GA, Jacobs MC, et al. 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: A randomized dose comparison. Blood Press Suppl 1994;3:23-30.
13. McKellar D, Holmes D. Study TIB 320: Long term efficacy and safety of spirapril (TI 211-950). Double-blind comparison of two different doses of captoril and hydrochlorothiazide. Sandoz Document Number 603-282, 1992.
14. Waite R, Lasance T, Mellein B. Study TIB 320: The multicenter evaluation of the long-term safety and efficacy of two different initial doses of spirapril (TI 211-950) in the treatment of mild to severe hypertension. Sandoz Document Number 603-258, 1991.
15. Reid JL. Editorial review. Hypertension 1988: Present challenges and strategies. J Hypertens 1988;6:3-8.
16. Conway J, Coats AJS, Radaelli A. Ambulatory blood pressure in relation to drug treatment and clinical trials. J Hypertens Suppl 1990;8:S83-S85.
17. Coats AJS. Reproducibility or variability of causal and ambulatory blood pressure data: Implications for clinical trials. J Hypertens Suppl 1990;8:S17-S20.
18. Weisser B, Mengden T, Vetter W. Ambulatory twenty-four hour blood pressure measurements in pharmacological studies. J Hypertens Suppl 1990;8:S87-S97.